The estimated Net Worth of Management Ltd Giuliani Mar... is at least $97.5 Milión dollars as of 29 December 2023. Management Mar owns over 65,803 units of Royalty Pharma plc stock worth over $68,825,506 and over the last few years Management sold RPRX stock worth over $28,670,815.
Management has made over 4 trades of the Royalty Pharma plc stock since 2023, according to the Form 4 filled with the SEC. Most recently Management sold 65,803 units of RPRX stock worth $1,845,116 on 29 December 2023.
The largest trade Management's ever made was selling 672,376 units of Royalty Pharma plc stock on 13 December 2023 worth over $19,451,838. On average, Management trades about 250,000 units every 4 days since 2023. As of 29 December 2023 Management still owns at least 2,477,520 units of Royalty Pharma plc stock.
You can see the complete history of Management Mar stock trades at the bottom of the page.
Over the last 4 years, insiders at Royalty Pharma plc have traded over $863,995,127 worth of Royalty Pharma plc stock and bought 5,330,350 units worth $152,553,456 . The most active insiders traders include David C Hodgson, William E Ford a Capital Partners Gp, L.L.C..... On average, Royalty Pharma plc executives and independent directors trade stock every 13 days with the average trade being worth of $7,420,205. The most recent stock trade was executed by Rory B Riggs on 2 January 2024, trading 470,000 units of RPRX stock currently worth $13,221,100.
royalty pharma is the industry leader in acquiring revenue-producing intellectual property – principally royalty interests in marketed and late stage biopharmaceutical products with $13 billion in assets. since inception in 1996, royalty pharma and its predecessors have invested approximately $5.8 billion to assemble a leading portfolio of royalty interests in pharmaceutical and biopharmaceutical products. royalty pharma’s strategy has been to acquire royalty interests in leading pharmaceutical and biotechnology products and hold these interests as part of a portfolio, seeking to diversify its revenue base across product and therapeutic classes. royalty pharma captures many of the strong and predictable aspects of the pharmaceutical industy while limiting the typical risks of biopharmaceutical companies. royalty pharma currently owns a diversified portfolio of royalty interests in several high- quality blockbuster biopharmaceutical products, including abbott’s humira®, j&j/merck’s remi
Royalty Pharma plc executives and other stock owners filed with the SEC include: